2282.HK

Casino operator MGM China Holdings Ltd. (2282.HK) said on Thursday its revenue rose 4% to $1 billion in the fourth quarter from $983 million a year earlier, crediting improved casino revenues due to a favorable hold rate compared with the prior year. The company’s full-year net revenue totaled $4 billion, up 28% from 2023.

MGM China reported net revenue of $1.1 billion, $1 billion and $929 million in each of the first three quarters of this year, respectively, representing double-digit gains for each period. The single-digit fourth-quarter gain shows the revenue growth is slowing sharply with the easing of a post-pandemic rebound.

The company said fourth-quarter occupancy rates for its MGM Macau and MGM Cotai resorts were 94.8% and 93.9%, respectively, roughly the same as 2023; but revenue per available room (revpar) fell sharply for both, with MGM Macau down 26% to HK$2,383 ($306) and MGM Cotai down 28% to HK$2,031.

Shares of MGM China opened up 4% at HK$10.1 on Thursday and continued to rise through the morning session. But the shares are still down around 25% from their high over the past six months.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click  here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…